Legend Biotech Yönetim

Yönetim kriter kontrolleri 1/4

Legend Biotech CEO'su Ying Huang, Sep2020 tarihinde atandı, in görev süresi 4.33 yıldır. şirketin hisselerinin 0.035% doğrudan sahiptir ve bu hisselerin değeri € 2.04M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 3.6 yıldır.

Anahtar bilgiler

Ying Huang

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	4.3yrs
CEO sahipliği	0.04%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

CEO

Ying Huang (51 yo)

4.3yrs

Görev süresi

Dr. Ying Huang, Ph D., is Chief Executive Officer of Legend Biotech Corporation since November 06, 2020 and serves as its Director since December 2021. He had been Chief Financial Officer of Legend Biotech...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ying Huang	CEO & Director	4.3yrs	Veri yok	0.035% € 2.0m
Jessie Yeung	Interim CFO	no data	Veri yok	Veri yok
Doug Wallace	Vice President of Global Operations	1.2yrs	Veri yok	Veri yok
Guowei Fang	Chief Scientific Officer & Head of Business Development	no data	Veri yok	Veri yok
Joanne Choi	Senior Manager of Investor Relations	no data	Veri yok	Veri yok
James Pepin	General Counsel	1.2yrs	Veri yok	Veri yok
Tim Roberts	Global Compliance Officer	less than a year	Veri yok	Veri yok
Deborah Wong	Executive Director of Strategic Marketing & Corporate Communications	no data	Veri yok	Veri yok
Elaine Qian	VP & Global Head of Human Resources	1.8yrs	Veri yok	Veri yok
Yuhong Qiu	Senior Vice President of Global Regulatory Affairs	3yrs	Veri yok	Veri yok
Alan Kick	Senior Vice President of Global Quality	3yrs	Veri yok	Veri yok
Mythili Koneru	Chief Medical Officer	1.8yrs	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 9LB 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ying Huang	CEO & Director	3.1yrs	Veri yok	0.035% € 2.0m
John M. Maraganore	Member of Strategic Advisory Board	1.8yrs	Veri yok	Veri yok
Li Zhu	Non-Independent Director	4.2yrs	Veri yok	Veri yok
Corazon Sanders	Independent Director	4.7yrs	Veri yok	0.010% € 610.4k
Xiaohui Ji	Independent Director	4.7yrs	Veri yok	0.0050% € 292.9k
Tomas Heyman	Independent Director	2.4yrs	Veri yok	0.0011% € 64.8k
Fangliang Zhang	Independent Chairman	2.4yrs	Veri yok	0% € 0
Ye Wang	Director	9.7yrs	Veri yok	0% € 0
Michel Vounatsos	Member of Strategic Advisory Board	1.8yrs	Veri yok	Veri yok
Wai Man Yau	Independent Director	4.7yrs	Veri yok	0.0010% € 59.5k
Patrick Casey	Independent Director	4.1yrs	Veri yok	0.0069% € 402.7k
Li Mao	Independent Director	2.4yrs	Veri yok	0.0019% € 110.3k

3.6yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 9LB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/09 21:33
Gün Sonu Hisse Fiyatı	2025/01/09 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Legend Biotech Corporation 27 Bu analistlerden 20, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ishan Majumdar	Baptista Research
Huidong Wang	Barclays
Konstantinos Biliouris	BMO Capital Markets Equity Research

Legend Biotech Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Legend Biotech Corporation Appoints Alan Bash as President of CARVYKTI®

Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024

Legend Biotech Corporation Appoints Peter Salovey as Independent Director, Effective August 9, 2024

Legend Biotech Corporation, Annual General Meeting, Sep 21, 2023

High number of new and inexperienced directors

Legend Biotech Corporation Elects Philip Yau as Director

Recent updates

Legend Biotech Corporation Announces New Results from the Phase 3 CARTITUDE-4 Study

Third quarter 2024 earnings released: US$0.68 loss per share (vs US$0.34 loss in 3Q 2023)

Legend Biotech Corporation Appoints Alan Bash as President of CARVYKTI®

New minor risk - Share price stability

Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024

Legend Biotech Achieves Breakthrough with Cilta-Cel Approval in China, Offering New Hope for Multiple Myeloma Patients

Second quarter 2024 earnings released: US$0.10 loss per share (vs US$1.14 loss in 2Q 2023)

Legend Biotech Corporation Appoints Peter Salovey as Independent Director, Effective August 9, 2024

Legend Biotech Corporation Announces Positive Overall Survival Results of Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

Legend Biotech Corporation Shares Data on the Earlier Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses At ASCO and EHA

Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.68 loss in 1Q 2023)

Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Full year 2023 earnings released: US$2.94 loss per share (vs US$2.81 loss in FY 2022)

Legend Biotech Provides Update on U.S. FDA and EMA Applications for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

Legend Biotech Announces U.S. FDA Label Update for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)

Legend Biotech Corporation Announces Patient-Reported Outcome (Pro) Data from the Phase 3 CARTITUDE-4 Study

Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.68 loss in 3Q 2022)

Legend Biotech Corporation, Annual General Meeting, Sep 21, 2023

Second quarter 2023 earnings released: US$1.14 loss per share (vs US$1.25 loss in 2Q 2022)

Legend Biotech Corporation Announces Submission of Supplemental Application to U.S. FDA for Expanded Use of CARVYKTI® (Ciltacabtagene Autoleucel)

Legend Biotech Corporation Announces Results from the Phase 3 CARTITUDE-4 Study

Legend Biotech Corporation Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI®? (Ciltacabtagene Autoleucel)

First quarter 2023 earnings released: US$0.68 loss per share (vs US$0.27 loss in 1Q 2022)

Legend Biotech Corporation to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350 million.

Full year 2022 earnings released

Second quarter 2022 earnings released: US$1.25 loss per share (vs US$0.66 loss in 2Q 2021)

Legend Biotech Corporation Announces Research and Development Update

Legend Biotech Receives Notification of Delinquency from The Nasdaq Stock Market LLC

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

Legend Biotech Corporation Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

High number of new and inexperienced directors

Legend Biotech Corporation Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

Legend Biotech Corporation Elects Philip Yau as Director

Legend Biotech Corporation Announces that CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech Corporation, Annual General Meeting, Oct 14, 2022

Legend Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Legend Biotech Corporation Announces Board Changes

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.61 loss in 1Q 2021)

Legend Biotech Corporation Legend Biotech Announces Termination of Its Phase 1 Clinical Trial Under Investigational New Drug Application for LB1901

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

Legend Biotech Corporation Announces U.S. FDA Clearance of IND Application for Solid Tumor Car-T, Lb1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.61 loss in 1Q 2021)

European Commission Grants Marketing Authorization to CARVYKTI of Legend Biotech Corporation

Legend Biotech Appoints Lori Macomber as Chief Financial Officer

High number of new and inexperienced directors

Legend Biotech Announces Executive Changes

Legend Biotech Corporation Announces Appointment of Guowei Fang as Global Head of Research and Early Development

Full year 2021 earnings released: US$2.74 loss per share (vs US$2.57 loss in FY 2020)

Legend Biotech Corporation's CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma

Legend Biotech Announces FDA Clinical Hold of Its Phase 1 Clinical Trial for LB1901

Forecast to breakeven in 2024

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $300 million.

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Legend Biotech Corporation Announces New and Updated Results from the Cartitude Clinical Development Program Studying Ciltacabtagene Autoleucel (Cilta-Cel) in the Treatment of Multiple Myeloma, Which Were Presented At the 63Rdamerican Society of Hematology (Ash) Annual Meeting and Exposition

Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.86 loss per share (vs US$0.50 loss in 3Q 2020)

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-Cd4 Car-T Therapy for Relapsed or Refractory T-Cell Lymphoma

Second quarter 2021 earnings released: US$0.66 loss per share (vs US$1.25 loss in 2Q 2020)

Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings

Legend Biotech Corporation Announces U.S. Food and Drug Administration Grants Bcma Car-T Cilta-Cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma

Legend Biotech Corporation Announces EMA Acceptance of the MAA for Cilta-Cel for RRMM